



## **First Molecular Characterisation of Clinical Strains of *Mycobacterium ulcerans* in Togo (West Africa)**

**Menssah Teko<sup>1,2\*</sup>, Mounerou Salou<sup>3</sup>, Solange E. Kakou Ngazoa<sup>4</sup>,  
Issaka Maman<sup>5</sup>, Kodjovi Agbodeka<sup>2</sup>, David Coulibaly N.<sup>4</sup>,  
Christiane Aby Amon<sup>4</sup>, Bahou Roger Dehe<sup>4</sup> and Yaovi Ameyapoh<sup>6</sup>**

<sup>1</sup>Centre Hospitalier Régional de Tsévié, Tsévié, Togo.

<sup>2</sup>Ecole Supérieure des Techniques Biologiques et Alimentaires, Université de Lomé, Lomé, Togo.

<sup>3</sup>Département des Sciences pharmaceutiques et biologiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo.

<sup>4</sup>Department of Technics and Technology, Platform of Molecular Biology, Pasteur Institute Abidjan, BP 490 Abidjan 01, Côte d'Ivoire.

<sup>5</sup>Institut National d'Hygiène, Lomé, Togo.

<sup>6</sup>Laboratoire de Microbiologie et de Contrôle de Qualité des Denrées Alimentaires, Ecole Supérieure des Techniques Biologiques et Alimentaires, Université de Lomé, Lomé, Togo.

### **Authors' contributions**

*This work was carried out in collaboration between all authors. Author MT designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Authors MS and SEKN managed the analyses of the study. Author YA managed the literature searches. All authors read and approved the final manuscript.*

### **Article Information**

DOI: 10.9734/MRJI/2018/v26i530076

#### Editor(s):

(1) Dr. Ng Zhi Xiang, Department of Biomedical Sciences, Faculty of Medicine, MAHSA University, Malaysia.

#### Reviewers:

(1) Gabor Ternak, University of Pécs, Hungary.

(2) Moses Mwajar Ngeiywa, University of Eldoret, Kenya.

Complete Peer review History: <http://www.sdiarticle3.com/review-history/46555>

**Original Research Article**

**Received 03 November 2018**

**Accepted 18 January 2019**

**Published 25 February 2019**

### **ABSTRACT**

**Background:** Buruli ulcer is the third most common mycobacterial disease worldwide. Cases most occur in 30 countries but severe cases occur in West Africa countries such as Benin, Cote d'Ivoire and Togo mainly in rural regions. Early diagnosis may prevent severe disability. The molecular technique seems the best solution and new Mycobacterial Interspersed Repetitive Units (MIRU) and

\*Corresponding author: E-mail: [tmroger2001@gmail.com](mailto:tmroger2001@gmail.com);

variable number tandem repeats (VNTR) typing method are the most reproducible in this regard. They propose geographical, inter and intraspecies differentiation and can be used as a diagnosis tool.

**Objective:** The objective of this study was to investigate the molecular diversity by using MIRU-VNTR typing in clinical samples of BU patients in Togo.

**Study Design:** 64 DNA extracts from clinical samples were collected from BU patients in the two principal endemic districts in Togo (Yoto and Zio) with three less endemic districts (Bas Mono, Lacs and Vo). First, IS2404 and KR real-time PCR plus IS2606 conventional PCR were performed. In a second step, the strains were analysed by PCR typing for five specific and sensitive markers MIRU1, VNTR6, ST1, VNTR19 and VNTR9.

**Results and Conclusion:** 71.11% were positive for IS2404, 3.13% were positives for PCR-KR and 31.11% for IS 2606. By MIRU-VNTR typing, 48.86% positive result was found for MIRU1 and 25.00%, 20.31%, 18.75% and 14.06% for VNTR6, ST1, VNTR19 and VNTR9 respectively. One of the samples was negative for all genotyping markers. Two different genetic profiles were identified by MIRU1, ST1 and VNTR loci by gel-analysed of the amplified products. The VNTR profile B (3,1,1,2) corresponding of 3 copies MIRU1, 1 copy VNTR6, 1 copy ST-1 and two copies of VNTR19 was detected in 15.63% of samples and the VNTR profile A (1,1,1,2) corresponding of 1 copy MIRU1, 1 copy VNTR6, 1 copy ST-1 and 2 copies of VNTR19 was detected in 3.13% of samples and confirms the West African genotype (3,1,1) in Togo. Different genetic strains of *Mycobacterium ulcerans* (*M. ulcerans*) were co-circulated in the same endemic region in the country. This study has described first the circulating of different genetic strains of *M. ulcerans* in Togo.

**Keywords:** Buruli ulcer; *M. ulcerans*; genotyping; MIRU-VNTR-typing; diversity; Togo; West Africa.

## 1. INTRODUCTION

*Mycobacterium ulcerans* is a slow-growing environmental mycobacterium, which causes significant morbidity and a disfiguring condition known as Buruli ulcer (BU). *M. ulcerans* infections have been found in more than 30 tropical and subtropical countries of Africa, Asia, Latin America and the Western Pacific but are most common and severe in West Africa [1,2] including rural parts of Benin, Cameroon, Côte d'Ivoire, Ghana and Togo. About 48% of reported cases in Africa are in children below 15 years, and both genders are equally affected. Recent reports describe increases in the incidence of BU in Australia [3,4], Benin [5] and Côte d'Ivoire [2]. In Togo, since the early 1990s patients with lesions clinically suspicious for Buruli ulcer disease (BUD) have been treated in Togolese hospitals. The first two laboratory-confirmed and well-documented BUD patients from Togo were described in 1996 by Meyers and colleagues [6]. According to data available at the Togolese Ministry of Health, from 1996 through 2004 more than 100 suspected BUD cases were notified and approximately 20% of these were Polymerase chain reaction (PCR) confirmed at the Institute for Tropical Medicine, Antwerp, Belgium. In 2004, a nation wide survey detected 1505 suspected cases of BUD ["Politique Nationale de Lutte contre L'Ulcère de Buruli." Ministère de la Santé, République Togolaise,

Lomé 2007] [7] and cases still increasing. The epidemiology of BU is poorly understood, but most foci are associated with slow-flowing or stagnant water; however, the natural reservoir of *M. ulcerans* remains unknown. *M. ulcerans* is often difficult to isolate from clinical specimens and usually requires 6 to 8 weeks to produce visible growth in primary culture [8,9]. Definitive identification of *M. ulcerans* is thus time-consuming; however, it can be recognised by microbiologic methods and classic molecular [10,11]. In the last decade, various DNA-based techniques have been used to classify mycobacteria [12,13]. All such studies have demonstrated a high taxonomic affiliation between *M. ulcerans* and *Mycobacterium marinum*. Discrimination of genetic variants has become an indispensable tool to unravel the evolution, epidemiology and transmission of pathogenic organisms and to gain insight into host-pathogen interactions [14,15]. In *M. ulcerans*, such elucidation is impossible due to a remarkable lack of genetic diversity on a local geographic scale [16]. Conventional genetic differentiation tools commonly used for phylogenetic profiling in *Mycobacterium tuberculosis*, such as restriction fragment length polymorphism, amplified fragment length polymorphism, variable-number tandem repeats (VNTR), and multilocus sequence typing, could distinguish between continental lineages only when applied to *M. ulcerans* [17]. Thus,

uncontrolled duplications and insertions of insertion sequences (ISEs) occur at relatively high frequency in replicating bacteria, leading to genomic insertions, deletions, and rearrangements that have the potential for molecular epidemiological applications. For *M. ulcerans*, two ISEs were defined, IS2404 and IS2606 [18,19]. Molecular detection for diagnosis based on Insertion Sequence 2404 has good specificity and high sensitivity for *M. ulcerans*, and then IS2404 is present in over 203 copies in the genome [20,17,21]. Previous studies have demonstrated different profiles of *M. ulcerans* by PCR-restriction profile and 16S rRNA sequencing [8,22]. The use of IS2404 restriction fragment length polymorphism (RFLP) analysis [23] led to the classification of *M. ulcerans* into six groups, including the isolate from Suriname as *M. ulcerans* type VI. The availability of complete genome sequences of *M. ulcerans* [17] allowed the identification of minisatellite markers including Mycobacterial Interspersed Repetitive Units (MIRUs) [16] and other novel tandem repeat loci [18]. Variable number tandem repeats (VNTR) typing is a promising typing tool for *M. ulcerans*, because analysis based on few loci already has a higher discriminatory power than other standard molecular typing methods. VNTR typing thus revealed for the first time genetic diversity within isolates from African countries [18]. The high resolution of VNTR is very useful in detecting heterogeneity among *M. ulcerans* in clinical and in environmental samples. Previous studies have recommended specific and sensitive VNTR loci to discriminate between *M. ulcerans* and Mycolactone producing mycobacteria (MPMs) [16,21,19,24]. Ecological

and Molecular epidemiological studies to identify reservoirs and transmission vectors are important for source tracking infections especially during outbreaks and elucidating transmission routes. Research efforts have therefore focused on genotyping strains of the mycobacteria from clinical and environmental samples. The study aimed to perform molecular characterisation of *Mycobacterium sp.* in clinical samples that circulate in Togo by using MIRU-VNTR typing.

## 2. MATERIALS AND METHODS

### 2.1 Ethical Approval

The study received approval from the Bioethics Committee for Health Research (CBRS) of Togo (N ° 21 / 2017 / CBRS of October 8, 2017) and the access to the data was authorised by the board of the National Program against Buruli Ulcer, Leprosis and Pian (Reference: 159/2015/MS/ DGS/ DSSP/ PNLUB-LP of November 20, 2015).

### 2.2 Clinical Sampling

90 DNA extracts from Buruli ulcer patients in Togo were selected. All patients were first clinically confirmed for BU by PCR IS 2404 positive and both are ZielhNeelsen positive in Togo. They were treated by recommended double antibiotic therapy. In Institute Pasteur of Cote d'Ivoire, before VNTR-MIRU typing, IS 2606 was performed, IS 2404 and KR PCR. 64 DNA extracts were selected for VNTR-MIRU typing (Fig. 1).




Fig. 1. DNA extracts selected for VNTR-MRU typing

64 clinical samples were selected from the Maritime Sanitary Region of Togo. Thirty-four (34) and 27 samples were collected from the most endemics districts namely Zio and Yoto respectively. Three (3) samples were collected from Bas-Mono, Lacs and Vo. 34 from females and 30 from males (Table 1). All of the isolates were selected to reflect both spatial and temporal diversity in Togo. Length polymorphism was estimated from the size of the PCR product following separation on agarose gel and based on included positive controls as described by previous studies [19,24]. *M. ulcerans* strains from Côte d'Ivoire (CI 25/2017) were used as positive controls for the VNTR typing.

### 2.3 DNA Extraction

The swab or FNA samples were first added to 15µl of Lysozyme and incubated 37°C 1hour in the thermomixer. DNA extraction was performed using extraction reagents Puregene Kit (Qiagen, UK) using the previous protocols [25]. Next added 10 µl of proteinase K incubated 55°C for 4 hours in the thermomixer or overnight. Then 230 µl of Protein Precipitation Solution (PPS) was added in icy bag. The DNA was precipitated by adding 1/10 volume of Sodium acetate 3M and 2 volumes of 70% Ethanol. The DNA was precipitated by adding 700 µl of isopropanol, 2 µl of glycogen and washed with 700 µl of ethanol 70%. The DNA was eluted in 500 µl of DNA/Rnase-free water. The control strain was *M. ulcerans* (ITM 9540) provided from Institute of Tropical Medicine (ITM), WHO Collaborating Center and Laboratory of Reference for Mycobacteria, Belgium.

### 2.4 PCR for *Mycobacterium ulcerans*

Target IS2404 located in the genome was specific for *M. ulcerans*. IS 2606 located in the genome was specific for *M. ulcerans* and *Mycobacterium lentiflavum*. KR was in the virulence plasmid (Table 3). Real-time PCR and PCR conventional were performed using PCR reagents Kit (Promega, Germany) using the previous protocols [26]. Briefly, the 25 µl-reaction contains 5 µl of DNA, 0.3 µM of each primer, 0.25 µM of labeled probe, and PCR-Mix. PCR consisted of 35 cycles of melting at 95°C for 5 sec; annealing and extension at 60°C for 1 min. Negative controls were performed with 5 µl of nuclease free-water. Positive controls DNA were tested in duplicate. The real-time PCR machine (Applied Biosystems, USA) was used and the fluorescence of FAM was measured to determine

the amplification threshold cycle (Ct). For the conventional PCR, the thermocycler Gene Amp®PCR System 9700 was used.

### 2.5 MIRU-VNTR Typing

The MIRU-VNTR-typing using PCR was running in a Thermocycler (GenAmp 9700, Applied Biosystems, USA) to amplify the MIRU1, the VNTR locus 6, VNTR locus 9 and the VNTR locus 19 in same parameters [27]. For *M. ulcerans* specific-VNTR target ST1, the PCR parameters were described by Hiltyet al. [19]. Briefly, 5 µl of extracted DNA was added to 45 µl PCR-Mix containing 0.2 mMd NTPs (Sigma, USA), 0.4 µM each primer, 1.5 mM MgCl<sub>2</sub> (Promega, Germany), 1X FlexiTaq-Polymerase buffer and 1 Unit Go-Flexi Taq Polymerase (Promega, Germany). All used primers were represented in (Table 2). The samples were tested by the 1/10 dilution for the detection of inhibitors. All PCR runs have included a negative control (sterile Dnase/Rnasefree water) for the test quality and the detection of contamination. Genomic DNA from ITM 9540 strain and strain from Cote d'Ivoire CI 25/2017 was tested as a positive control for the MIRU-VNTR-typing tests.

### 2.6 Visualisation of Amplified Products

Each sample was tested in simplex Typing-PCR for the five loci and 15 µl amplicons were analysed in 1.5% Agarose gel by electrophoresis. The polymorphism was detected in different size of the amplicons. The size of the amplicons was estimated by comparison with the 100-bp Ladder (Eurobio, France).

## 3. RESULTS

A total of 64 clinical samples were selected from Maritime Sanitary Region of Togo, mainly 53.12% from Zio and 42.19% from Yoto the most endemics districts and 4.69% from Vo, Lacs and Bas-Mono (Fig. 2). Result shows 53.13% from females and 46.87% from males. Patients were 2 to 70 years old.

By using real-time PCR with target IS2404, 71.11% were found positive for *M. ulcerans*. The detected threshold cycle (Ct) of real-time PCR-IS2404 was low (Ct: 3.816 – 26.472) and indicated the high bacterial level of *M. ulcerans* in 14 samples (21.88% of cases) while 50 samples (78.12% of cases) have a high detected threshold cycle (Ct: 27.264 – 38.382) indicated a low bacterial load. For PCR-KR only two samples

**Table 1. Clinical DNA extracts isolated from 2015 to 2017 in Zio, Yoto and Bas-Mono BU endemics districts selected for VNTR-MIRU typing**

Strain	Sex	Age	Village	District	Year of extraction	Strain	Sex	Age	Village	District	Year of extraction
TG0115	F	12	FRANGADUA	ZIO	2015	<b>TG3315</b>	F	60	TCHEKPO ANAGALI	YOTO	2015
TG0215	F	50	GATI	ZIO	2015	<b>TG3416</b>	M	12	GATI SUN	ZIO	2016
TG0315	F	9	TABLIGBO ADETICOPE	YOTO	2015	<b>TG3516</b>	F	14	TCHEKPO DEVE	YOTO	2016
TG0415	M	10	FONGBE APEDOME	ZIO	2015	<b>TG3616</b>	F	20	TCHEKPO DEVE	YOTO	2016
TG0515	F	48	FONGBE APEDOME	ZIO	2015	<b>TG3716</b>	F	8	TCHEKPO AVEDJI	YOTO	2016
TG0615	M	5	GATI SUN	ZIO	2015	<b>TG3816</b>	F	8	GATI AGODOU	ZIO	2016
TG0715	F	5	FONGBE BOETI	ZIO	2015	<b>TG3916</b>	M	5	FONGBE ZOGBEDJI	ZIO	2016
TG0815	F	14	GAPE AGOCOPE	ZIO	2015	<b>TG4016</b>	M	30	TCHEKPO DEVE AGBEDJIKO	YOTO	2016
TG0915	F	8	GATI SUN	ZIO	2015	<b>TG4116</b>	M	2	TCHEKPO DEDEKPOE	YOTO	2016
TG1015	F	7	TCHEKPO DEVE	YOTO	2015	<b>TG4216</b>	F	45	TCHEKPO DEVE	YOTO	2016
TG1115	M	8	FONGBE APEDOME	ZIO	2015	<b>TG4316</b>	M	48	FONGBE ZOGBEDJI	ZIO	2016
TG1215	M	12	GATI SUN	ZIO	2015	<b>TG4416</b>	F	9	FONGBE APEDOME	ZIO	2016
TG1315	M	14	KODZO	ZIO	2015	<b>TG4516</b>	M	6	FONGBE APEDOME	ZIO	2016
TG1415	M	15	FONGBE ZOGBEDJI	YOTO	2015	<b>TG4616</b>	M	19	GATI SUN	ZIO	2016
TG1515	F	5	TCHEKPO ANAGALI	YOTO	2015	<b>TG4716</b>	M	6	TCHEKPO ANAGALI	YOTO	2016
TG1615	M	8	TCHEKPO DEDEKPO	YOTO	2015	<b>TG4816</b>	F	32	TCHEKPO DEVE	YOTO	2016
TG1715	M	2	TCHEKPO ANAGALI	YOTO	2015	<b>TG4916</b>	M	3	TCHEKPO DEDEKPOE AVEGODOE	YOTO	2016
TG1815	F	15	KODZO	ZIO	2015	<b>TG5016</b>	M	12	GATI SUN	ZIO	2016
TG1915	F	11	GATI AGODOU	ZIO	2015	<b>TG5116</b>	F	10	GATI SUN	ZIO	2016
TG2015	M	6	TCHEKPO DEDEKPOE	YOTO	2015	<b>TG5216</b>	F	19	FONGBE APEDOME	ZIO	2016
TG2115	M	15	AGBATA	LACS	2015	<b>TG5316</b>	F	6	GATI SUN	ZIO	2016
TG2215	M	11	GATI AGODOU	ZIO	2015	<b>TG5416</b>	F	10	TCHEKPO DEDEKPOE	YOTO	2016
TG2315	F	9	ADANGBE LAKOTO	ZIO	2015	<b>TG5516</b>	F	58	TCHEKPO AVEDJI	YOTO	2016
TG2415	M	6	GATI AGODOU	ZIO	2015	<b>TG5616</b>	F	70	FONGBE APEDOME	ZIO	2016
TG2515	M	7	FONBGE ZOGBEDJI	ZIO	2015	<b>TG5716</b>	F	60	TCHEKPO-DEVE	YOTO	2016
TG2615	F	34	TCHEKPO DEVE	YOTO	2015	<b>TG5816</b>	M	62	BATONOU	BAS MONO	2016
TG2715	M	8	YOBO TOUME	ZIO	2015	<b>TG5917</b>	M	4	GATI AGODOU	ZIO	2017
TG2815	M	9	TCHEKPO DEDEKPOE	YOTO	2015	<b>TG6017</b>	F	13	AKOUMAPE	VO	2017
TG2915	F	50	TCHEKPO ANAGALI	YOTO	2015	<b>TG6117</b>	M	13	GATI AGODOU	ZIO	2017
TG3015	F	9	TCHEKPO DEDEKPOE	YOTO	2015	<b>TG6217</b>	F	7	FONGBE ZOGBEDJI	ZIO	2017
TG3115	F	10	TCHEKPO ANAGALI	YOTO	2015	<b>TG6317</b>	F	14	GATI AKPAFO	ZIO	2017
TG3215	M	11	TCHEKPO DEDEKPOE	YOTO	2015	<b>TG6417</b>	M	10	TCHEKPO DEVE	YOTO	2017

**Table 2. Primers used in this study**

<b>Target</b>	<b>Oligos</b>	<b>Primer sequence (5'-3')</b>	<b>References</b>
IS2404	IS2404 F	ATTGGTGCCGATCGAGTTG	[21,28,29]
	IS2404 R	TCGCTTTGGCGCGTAAA	
	IS2404probe	6 FAM-CACCACGCAGCATTCTTGCCGT-TAMRA	
IS2606	IS2606 F	CCGTACAGACCAGGAAGAAG	
	IS2606 R	TGCTGACGGAGTTGAAAAACC	
Ketoreductase	KR F	TCACGGCCTGCGATATCA	
	KR R	TTGTGTGGGCACTGAATTGAC	
	KR-probe	6 FAM-ACCCCGAAGCACTG-TAMRA	
MIRU1	MIRU1 F	GCTGGTTCATGCGTGGAAG	
	MIRU1 R	GCCCTCGGGAATGTGGTT	
VNTR6	Locus 6 F	GACCGTCATGTCGTTTCGATCCTAGT	
	Locus 6 R	GACATCGAAGAGGTGTGCCGTCT	
ST1	ST1 F	CTGAGGGGATTCACGACCAG	
	ST1 R	CGCCACCCGCGGACACAGTCG	
VNTR-19	Locus 19F	CCGACGGATGAATCTGTAGGT	
	Locus 19R	TGGCGACGATCGAGTCTC	
VNTR-9	Locus 9F	GCCGAAGCCTTGTGGACC	
	Locus 9R	GTTTTCCCGCAGCATCTCG	

Table 3. PCR diagnostics for *M. ulcerans*

N°	Strains	Diagnostics tests			N°	Strains	Diagnostics tests		
		PCR IS2404(Ct)	PCR IS 2606	PCR KR (Ct)			PCR IS2404(Ct)	PCR IS2606	PCR KR (Ct)
1	TG0115	24,991	POSITIVE	Undetermined	33	TG3316	34,411	NEGATIVE	Undetermined
2	TG0215	24,312	POSITIVE	Undetermined	34	TG3416	31,425	POSITIVE	Undetermined
3	TG0315	30,535	NEGATIVE	Undetermined	35	TG3516	23,939	POSITIVE	Undetermined
4	TG0415	38,065	POSITIVE	Undetermined	36	TG3616	31,884	NEGATIVE	Undetermined
5	TG0515	23,554	POSITIVE	Undetermined	37	TG3716	33,856	NEGATIVE	Undetermined
6	TG0615	29,584	POSITIVE	Undetermined	38	TG3816	34,600	NEGATIVE	Undetermined
7	TG0715	32,255	POSITIVE	Undetermined	39	TG3916	30,424	NEGATIVE	Undetermined
8	TG0815	22,275	POSITIVE	Undetermined	40	TG4016	34,736	NEGATIVE	Undetermined
9	TG0915	33,343	NEGATIVE	Undetermined	41	TG4116	24,686	NEGATIVE	Undetermined
10	TG1015	23,513	POSITIVE	Undetermined	42	TG4216	34,197	POSITIVE	Undetermined
11	TG1115	32,520	NEGATIVE	Undetermined	43	TG4316	33,134	NEGATIVE	Undetermined
12	TG1215	32,523	POSITIVE	Undetermined	44	TG4416	36,054	POSITIVE	Undetermined
13	TG1315	30,062	NEGATIVE	7,940	45	TG4516	28,144	POSITIVE	Undetermined
14	TG1415	30,095	POSITIVE	Undetermined	46	TG4616	27,475	POSITIVE	Undetermined
15	TG1515	31,714	NEGATIVE	Undetermined	47	TG4716	26,473	POSITIVE	Undetermined
16	TG1615	35,324	NEGATIVE	Undetermined	48	TG4816	3,817	NEGATIVE	Undetermined
17	TG1715	24,089	POSITIVE	Undetermined	49	TG4916	34,932	NEGATIVE	Undetermined
18	TG1815	32,182	NEGATIVE	Undetermined	50	TG5016	33,164	NEGATIVE	Undetermined
19	TG1915	22,923	POSITIVE	Undetermined	51	TG5116	36,467	POSITIVE	Undetermined
20	TG2015	37,196	NEGATIVE	Undetermined	52	TG5216	29,872	NEGATIVE	Undetermined
21	TG2115	37,602	NEGATIVE	Undetermined	53	TG5316	38,383	POSITIVE	Undetermined
22	TG2215	24,433	POSITIVE	Undetermined	54	TG5416	37,906	NEGATIVE	Undetermined
23	TG2315	35,040	POSITIVE	Undetermined	55	TG5516	31,719	NEGATIVE	Undetermined
24	TG2415	25,658	NEGATIVE	Undetermined	56	TG5616	32,962	NEGATIVE	Undetermined
25	TG2515	32,572	POSITIVE	Undetermined	57	TG5716	37,361	NEGATIVE	Undetermined
26	TG2615	25,546	NEGATIVE	Undetermined	58	TG5816	37,342	POSITIVE	Undetermined
27	TG2715	27,361	POSITIVE	Undetermined	59	TG5917	38,140	NEGATIVE	Undetermined
28	TG2815	31,505	POSITIVE	8,465	60	TG6017	36,471	NEGATIVE	Undetermined
29	TG2915	27,265	POSITIVE	Undetermined	61	TG6117	30,535	NEGATIVE	Undetermined
30	TG3015	35,427	NEGATIVE	Undetermined	62	TG6217	37,361	NEGATIVE	Undetermined
31	TG3115	35,308	NEGATIVE	Undetermined	63	TG6317	38,383	NEGATIVE	Undetermined
32	TG3215	31,799	POSITIVE	Undetermined	64	TG6417	37,361	NEGATIVE	Undetermined
<b>Positivity rate</b>		<b>PCR IS 2404</b>	<b>PCR IS 2606</b>		<b>PCR KR</b>				
		<b>100.00% (64/64)</b>	<b>32.81% (21/64)</b>		<b>3.13% (2/64)</b>				

Table 4. MIRU-VNTR-typing of clinical strains in this study

N°	Strains	Copies detected					VNTR profile designation	District
		MIRU 1 (509 bp)	LOCUS 6 (500 bp)	ST1 (400 bp)	VNTR 19 (500 bp)	VNTR 9 (550 bp)		
1	TG0115	1	1	1	2	-	1,1,1,2,-	ZIO
2	TG0215	3	1	1	2	-	3,1,1,2,-	ZIO
3	TG0315	-	-	-	-	-	ND	YOTO
4	TG0415	-	-	-	-	-	ND	ZIO
5	TG0515	3	1	1	2	-	3,1,1,2,-	ZIO
6	TG0615	-	-	-	-	-	ND	ZIO
7	TG0715	3	1	1	-	-	3,1,1,-,-	ZIO
8	TG0815	1	1	1	2	-	1,1,1,2,-	ZIO
9	TG0915	-	-	-	-	-	ND	ZIO
10	TG1015	1	-	1	2	-	1,-,1,2,-	YOTO
11	TG1115	-	-	-	-	-	ND	ZIO
12	TG1215	3	1	-	-	-	ND	ZIO
13	TG1315	-	-	-	-	-	ND	ZIO
14	TG1415	-	1	-	-	-	ND	YOTO
15	TG1515	-	-	-	-	-	ND	YOTO
16	TG1615	-	-	-	-	-	ND	YOTO
17	TG1715	3	1	1	2	-	3,1,1,2,-	YOTO
18	TG1815	-	-	-	-	-	ND	ZIO
19	TG1915	3	1	1	2	-	3,1,1,2,-	ZIO
20	TG2015	-	-	-	-	-	ND	YOTO
21	TG2115	-	1	-	-	-	ND	LACS
22	TG2215	3	1	1	2	2	3,1,1,2,2	ZIO
23	TG2315	-	-	-	-	2	ND	ZIO
24	TG2415	3	1	-	-	-	ND	ZIO
25	TG2515	-	-	-	-	2	ND	ZIO
26	TG2615	3	-	-	-	-	ND	YOTO
27	TG2715	3	-	-	-	-	ND	ZIO
28	TG2815	-	-	-	-	2	ND	YOTO
29	TG2915	3	-	-	-	2	ND	YOTO
30	TG3015	3	-	-	-	-	ND	YOTO
31	TG3115	3	-	-	-	-	ND	YOTO
32	TG3215	3	-	-	-	2	ND	YOTO



33	TG3316	3	-	-	-	-	-	ND	YOTO
34	TG3416	-	-	-	-	-	-	ND	ZIO
35	TG3516	3	1	1	2	-	3,1,1,2,-	B	YOTO
36	TG3616	-	-	-	-	-	-	ND	YOTO
37	TG3716	-	-	-	-	-	-	ND	YOTO
38	TG3816	-	-	-	-	-	-	ND	ZIO
39	TG3916	3	-	-	-	-	-	ND	ZIO
40	TG4016	-	-	-	-	-	-	ND	YOTO
41	TG4116	3	1	1	2	2	3,1,1,2,2	B	YOTO
42	TG4216	-	-	-	-	-	-	ND	YOTO
43	TG4316	-	-	-	-	2	-	ND	ZIO
44	TG4416	-	-	-	-	-	-	ND	ZIO
45	TG4516	3	1	1	2	-	3,1,1,2,-	B	ZIO
46	TG4616	-	-	-	-	-	-	ND	ZIO
47	TG4716	3	1	1	2	-	3,1,1,2,-	B	YOTO
48	TG4816	-	-	-	-	-	-	ND	YOTO
49	TG4916	-	-	-	-	2	-	ND	YOTO
50	TG5016	-	-	-	-	-	-	ND	ZIO
51	TG5116	-	-	-	-	-	-	ND	ZIO
52	TG5216	3	-	-	-	-	-	ND	ZIO
53	TG5316	-	-	-	-	-	-	ND	ZIO
54	TG5416	-	-	-	-	-	-	ND	YOTO
55	TG5516	3	-	-	-	-	-	ND	YOTO
56	TG5616	3	-	-	-	-	-	ND	ZIO
57	TG5716	3	-	-	-	-	-	ND	YOTO
58	TG5816	-	-	-	-	-	-	ND	BAS MONO
59	TG5917	-	-	-	-	-	-	ND	ZIO
60	TG6017	-	-	-	-	-	-	ND	VO
61	TG6117	-	-	-	-	-	-	ND	ZIO
62	TG6217	3	-	-	-	-	-	ND	ZIO
63	TG6317	3	-	-	-	-	-	ND	ZIO
64	TG6417	3	-	-	-	-	-	ND	YOTO
Positivity rate		<b>48.87% (30/64)</b>	<b>25.00% (16/64)</b>	<b>20.31% (13/64)</b>	<b>18.75% (12/64)</b>	<b>14.06% (9/64)</b>			

(3.13%) were positives with low CT (7.940 and 8.465). They were positives for IS2404 and the bacterial loads were low when the potential mycolactonpolyketide producing is high. For PCR-IS2606, conventional PCR was performed and the size of the amplicons revealed positives cases. 28 samples were positives (31.11%) with 21 (32.81%) simultaneously positives to IS2404 (Table 3).

Five MIRU-VNTR genotyping markers for molecular characterisation were performed on the 64 DNA extract. MIRU 1 was the most amplified for 48.86% of the samples followed by VNTR locus 6 (25.00%), ST1 (20.31%), VNTR locus 19 (18.75%) and VNTR locus 9 (14.06%). 4.69% (3/64) were positives for 5 genotyping markers, 14.06% (9/64) for 4 genotyping markers and 42.19% (27/64) were negative for all markers (Table 4). The detection of MIRU1 has shown two amplified products corresponding to one copy and three copies of 53 bp-repeat sequences. For Locus 6, 100% of the amplified products are one copy (400 bp). The same for ST1, Locus 19 and Locus 9 which amplified

products were respectively one copy (500 bp), two copies (500 bp) and two copies (500 bp). Those copies are repeated in the *M. ulcerans* genome. The amplified product's size corresponded to the togolese strains polymorphism and molecular characterisation by MIRU-VNTR typing. The VNTR profile (3,1,1,2,-) is the most represented and corresponding to African *M. ulcerans* strain (3,1,1) and VNTR profile B (3,1,1) for 83.33% (10/12) matching. The VNTR profile (1,1,1,2,-) were represented for 16.67% (2/12) and were the VNTR profile A. The VNTR profile B was sampled from Yoto district and Zio district and the VNTR profile A were just from Zio district. Others profiles were identified. Three copies for MIRU1 were amplified for different profiles as 20.31% for the profile (3,-,-,-,-), 3.13% for (3,-,-,-,2) and (3,1,-,-,-) and in other hand 1.56% for (3,1,1,-,-). VNTR locus 9 only were matching for 7.81% (5/64) by profile (-,-,-,-,2). The represented profile 28.13% (18/64) were (-,-,-,-,-) with any genotyping marker matching. Both diverse profiles were sampling in all districts of Togo. The control strain from Cote d'Ivoire has shown VNTR-profile C (3,1,2,2) (Fig. 3, Table 4).





Fig. 2. Maps of Togo and the two endemics districts of Yoto and Zio showing the localities from which strains originated



**Fig. 3. Agarose gel analysis of MIRU-VNTR typing of clinical samples, CN: Negative control DNA/Rnase free water, CP: Positive control DNA Ci25/2017, M: 100 bp-DNA Ladder (Promega, Germany)**

#### 4. DISCUSSION

The identification of mycobacterial species constitutes a critical step in patient management because the results obtained influence the choice of appropriate treatment. Classical procedures to establish the species of mycobacteria based on conventional biochemical tests can take several weeks and may generate inaccurate diagnoses. For *M. ulcerans*, there are only a few phenotypic characteristics, making additional molecular tests essential for conclusive identification. PCR-based methods offer several advantages including speed, sensitivity and specificity [22]. All of the DNA extracts were sampled from endemics districts of Togo by conventional PCR and were from Buruli patients of Centre National de reference d'ulcere de Buruli de Tsevie in Togo. The study realised that qPCRs for IS 2404 and KR, conventional PCR for IS2606. These three qPCRs served to measure the relative amounts of *M. ulcerans* DNA in the samples and to determine the IS2404: IS2606 copy number ratio which differentiates *M. ulcerans* from the other MPM. According to Fyfe et al., *M. ulcerans susp ulcerans*, responsible for outbreak in Africa were  $\Delta Ct$  (IS2606-IS2404) ranged from 2.77 (for 104 genomes) to 4.1 (for 0.1 genome) and  $\Delta Ct$  between the KR and IS2404 assays increased from 1.3 (for 104 genomes) to 4.3 (for 0.1 genomes) but was generally less than that for the  $\Delta Ct$ (IS2606-IS2404). Although IS2606 conventional PCR was performed, only 32.81% (21/64) samples were positives simultaneously for IS2404 and IS2606 and 67.19% were positives only for IS2404. These results conduct to investigate more about *M. ulcerans* species whether there are more mycolactone producing

mycobacteria. Relatively the sample's IS2404 Ct, (3.816 – 26.472) and (27.264 – 38.382) for respectively more than 200.000 to 200 copies and 0.2 to 200 copies of the genome the genome quantity were few. The few quantities of KR-PCR positive can be associated with the plasmid gene loss. Further investigation may be led to discriminate *M. ulcerans* to mycolactone producing mycobacteria by Christelle D et al. [28] based on 16S rRNA and IS2404 sequences confirmed that 94% of the clinical samples contained MPMs. Although q PCR was 10 to 10000 times more sensitive than classic PCR, a false-negative PCR may be caused by the time between collection and testing of the specimen or technical limitations [29]. Current typing methods for *M. ulcerans* are capable of resolving only geographical types and are consequently limited in their discriminatory power. The availability of *M. ulcerans* genome sequences presents an enormous resource for the identification of potential markers that are useful for indexing polymorphisms within the species. Since Stragier et al., MIRUs, besides intraspecies and interspecies differentiation among the *M. ulcerans*-*M. marinum* complex, MIRU-VNTR typing is a highly reproducible method that can also be applied directly to clinical specimens. All African *M. ulcerans* isolates had three copies of MIRU motifs at locus 1 and differed from all other isolates. Although based on Kakou et al. [30] on four specific MIRU-VNTR typing markers and Lavender et al. whose included VNTR Locus 9 as specific marker indicated origin of environmental strain in human contaminations, the present study performed five markers as MIRU1, VNTR locus 6, ST1, VNTR locus 19 and VNTR locus 9 to elucidate the diversity among strains circulate in

Togo. Both strains conserved all five loci confirm previous studies that the togolese strains were African strains (3,1,1) when considered in order MIRU1, Locus 6 and ST1. And there were two MIRU-VNTR profiles circulated as A and B when considered in order MIRU1, Locus 6, ST1 and VNTR 9. The results as Stragier et al. [31] showed that the profile B as (3,1,1,2) were predominant. The repeat variations of 1 and 3 for MIRU 1 suggest the presence of genetic diversity in MPM strains from Togo. This length polymorphism in MIRU 1 also explained the limited but shared homology with isolates from Ghana, as well as the overall genetic differentiation between the two countries. In Ghana, only one allele was reported for MIRU 1 and ST1 in contrast to two for both Locus 6 and Locus 19. In this study, two alleles were seen only in MIRU 1. This suggests that MIRU 1 may be more informative for typing isolates in Togo. However, a larger sample size is needed to estimate the genetic diversity in these MPM populations. An ST1 monomorphic repeat of two is inconsistent with findings in Ghana where there was a polymorphism for the locus. Interestingly, the allelic profile (3,1,1,2) is similar to *M. ulcerans* B genotype, circulating in West Africa. Similar allelic profiles at some loci, e.g., (3,1,1,-) or (3,1,-,-) or (3,-,-,-) suggest orthology to VNTR profile B (3,1,1,2) and (-, 1,-, -) suggest orthology to B (3,1,1,2) or A (1,1,1,2) carried by some Ghanaian isolates [19]. This may suggest similar strain lineages between Togo and Ghana. A part of MIRU 1, which amplified product reveal polymorphism with two different copies 1 and 3, all the loci reveal a uniformity among togolese strains. Phylogenetic clustering on the basis of genetic diversity in the MIRU 1 locus showed two main *M. ulcerans* lineages in Togo. More again, this study reveals only one allele of Locus 6, ST1, Locus 19 with respectively one copy and two copies.

## 5. CONCLUSION

The study successfully demonstrated that the shared length polymorphisms at the VNTR loci in Togolese strains and other studies in both Côte d'Ivoire and Ghana suggest common ancestral lineages. Complementation of sequence and length polymorphism data should potentially increase the discriminatory power of the VNTR-typing method. It is envisaged that this approach would be more useful for genotyping *M. ulcerans* and other highly monomorphic species. The allelic copy number in MIRU 1 suggests diversity in *M. ulcerans* strains from Togo. Using

standardised genotyping protocols from Cote d'Ivoire and Ghana allowed the comparison of datasets. The latter could help explain the role of different ecologies and demography in BU. This study also suggests that the distribution of *M. ulcerans* type in two BU endemic districts not be significantly different.

## CONSENT

As per international standard or university standard written participant consent has been collected and preserved by the authors.

## ETHICAL APPROVAL

The study was received approval from the Bioethics Committee for Health Research (CBRS) of Togo (N ° 21 / 2017 / CBRS of October 8, 2017) and the access to the data was authorised by the board of the National Program against Buruli Ulcer, Leprosis and Pian (Reference: 159/2015/MS/ DGS/ DSSP/ PNLUB-LP of November 20, 2015).

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer, *Mycobacterium ulcerans* infection. World Health Organization, Geneva, Switzerland; 2000.
2. Marston BJ, Diallo MO, Horsburgh CR, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am. J. Trop. Med. Hyg. 1995;52:219–224.
3. Flood P, Street A, O'Brien P, Hayman J. *Mycobacterium ulcerans* infection on Philip Island, Victoria. Med. J. Aust. 1994;160: 160.
4. Johnson PD, Veitch MG, Leslie DE, et al. The emergence of *Mycobacterium ulcerans* in Melbourne. Med. J. Aust. 1996;164:76-78.
5. Josse R, Guedenon A, Aguiar J, Anagonou S, et al. L'ulcere de Buruli, une pathologie peu connue au Benin. A propos de 227 cas. Bull. Soc. Pathol. Exot. 1994;87:170-175.
6. Meyers WM, Tignokpa N, Priuli GB, Portaels F. *Mycobacterium ulcerans* infection (Buruli ulcer): first reported

- patients in Togo. *Br J Dermatol.* 1996;134: 1116–1121.
7. WHO. Buruli ulcer: First programme review meeting for West Africa - summary report. *Wkly Epidemiol Rec.* 2009;84:43–48.
  8. Portaels F, Fonteyne PA, de Beenhouwer H, et al. Variability in the 3' end of 16S rRNA sequences of *Mycobacterium ulcerans* is related to geographic origin of isolates. *J. Clin. Microbiol.* 1996;34:962–965.
  9. Portaels F. Basic microbiology, p. 23–30. In K. Asiedu, R. Scherpbies, and M. Raviglione (ed.), *Buruli ulcer: Mycobacterium ulcerans infection*. WHO/CDS/CPE/GBUI/2000. World Health Organization, Geneva, Switzerland; 2000.
  10. Kox LFF, van Leeuwen J, Knijper S, et al. PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. *J. Clin. Microbiol.* 1995;33: 3225–3233.
  11. Roberts B. Molecular and immunological studies of mycobacterium ulcerans. Ph. D. thesis. James Cook University, Cairne, Australia; 1997.
  12. Brosch R, Pym AS, Gordon SV, Cole ST. The evolution of mycobacterial pathogenicity: clues from comparative genomics. *Trends Microbiol.* 2001;9:452–458.
  13. Gagneux S, Small PM. Global phylogeography of *Mycobacterium tuberculosis* and implications for tuberculosis product development. *Lancet Infect. Dis.* 2007;7:328–337.
  14. Kaser M, Gutmann O, Hauser J, Stinear T, et al. Lack of insertional-deletional polymorphism in a collection of *Mycobacterium ulcerans* isolates from Ghanaian Buruli ulcer patients. *J. Clin. Microbiol.* 2009;47:3640–3646.
  15. Stragier P, Ablordey A, Durnez L, Portaels F. VNTR analysis differentiates *Mycobacterium ulcerans* and IS2404 positive mycobacteria. *Syst. Appl. Microbiol.* 2007;30:525–530.
  16. Stragier P, Ablordey A, Meyers WM, Portaels F. Genotyping *Mycobacterium ulcerans* and *Mycobacterium marinum* by using mycobacterial interspersed repetitive units. *J. Bacteriol.* 2005;187:1639–1647.
  17. Stinear TP, Seemann T, Pidot S, et al. Reductive evolution and niche adaptation inferred from the genome of *Mycobacterium ulcerans*, the causative agent of Buruli ulcer. *Genome Res.* 2007;17:192-200.
  18. Ablordey A, Swings J, Hubans C, Chemlal K, Loch C, Portaels F, Supply PM. *Ulcerans* multilocus variable-number tandem repeat typing of mycobacterium ulcerans. *Journ Clin Microbiol.* 2005;43:1546-1551.
  19. Hilty M, Yeboah-Manu D, Boakye D, Mensah-Quainoo E, Rondini S, Schelling E, Ofori-Adjei D, Portaels F, Zinsstag J, Pluschke G. Genetic diversity in *Mycobacterium ulcerans* isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. *J Bacteriol.* 2006;188:1462-1465.
  20. Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, Johnson P. Development of a PCR assay for rapid diagnosis of *Mycobacterium ulcerans* infection. *Journ Clin Microbiol.* 1997;35:1696-1700.
  21. Fyfe JAM, Lavender CJ, Johnson PDR, Globan M, Sievers A, Azuolas J, Stinear TP. Development and application of two *M. ulcerans* multiplex real-time PCR assays for the detection of *Mycobacterium ulcerans* in clinical and environmental samples. *Appl Environ Microbiol.* 2007;73:4733-4740.
  22. Chemlal K, Huys G, Fonteyne PA, Vincent V, Lopez AG, Rigouts L, Swings J, Meyers WM, Portaels F. Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism finger printing for identification and typing of *Mycobacterium ulcerans* and *Mycobacterium marinum*. *Journ Clin Microbiol.* 2001;39:3272-3278.
  23. Chemlal K, De Ridder K, Fonteyne PA, Meyers WM, Swings J, Portaels F. The use of IS 2404 restriction fragment length polymorphism suggests the diversity of *Mycobacterium ulcerans* from different geographical areas. *Am. J. Trop. Med. Hyg.* 2001;64:270–273.
  24. Lavender CJ, Stinear T, Johnson PDR, Azuolas J, Benbow ME, Wallace JR, Fyfe JAM. Evaluation of VNTR typing for the identification of *Mycobacterium ulcerans* in environmental samples from Victoria, Australia. *FEMS Microbiol Lett.* 2008;287:250-255.
  25. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, van Vloten F, Kruppa T, Fleischer B, Bretzel G. Dry-reagent-based

- PCR as a novel tool for laboratory confirmation of clinically diagnosed *Mycobacterium ulcerans*-associated disease in areas in the tropics where *M. ulcerans* is endemic. *J Clin Microbiol.* 2005;43:271-6.
26. Ngazoa-Kakou ES, Ekaza E, Aka N, Coulibaly-N' Golo D, Coulibaly B, Dosso M. Evaluation of real-time PCR for *Mycobacterium ulcerans* in endemic region in Côte d'Ivoire. *Afri Journ Microbiol Res.* 2011;16:2211-2216.
  27. Williamson HR, Benbow ME, Nguyen KD, Beachboard DC, Kimpbrauskas RK, et al. Distribution of *Mycobacterium ulcerans* in Buruli ulcer endemic and non-endemic aquatic sites in Ghana. *PLoS Negl Trop Dis.* 2008;2:1-14.
  28. Christelle Dassi, Lydia Mosi, Charles A. Narh, Charles Quaye, Danièle O. Konan, Joseph A. Djaman, Bassirou Bonfoh. Distribution and Risk of Mycolactone-Producing *Mycobacteria* Transmission within Buruli Ulcer Endemic Communities in Côte d'Ivoire. *Trop. Med. Infect. Dis.* 2017;2:3.
  29. Vanechoutte M, Van Eldere J. The possibilities and limitations of nucleic acid amplification technology in diagnostic microbiology. *J. Med. Microbiol.* 1997;46:188-194.
  30. Kakou Ngazoa E. Solange, Coulibaly N. David, AkaNguetta, Vakou Sabine, Aoussi Serge and Dosso Mireille. Clonality of *Mycobacterium ulcerans* by using VNTR-MIRU Typing in Ivory Coast (Côte d'Ivoire), West Africa. *IJTDH.* 2015.0697(4): 163-171
  31. Pieter Stragier, Anthony Ablordey, L. Manou Bayonne, Yatta L. Lugor, Ireneaus S. Sindani, Patrick Suykerbuyk, Henry Wabinga, Wayne M. Meyers, Françoise Portaels. Heterogeneity among *Mycobacterium ulcerans* Isolates from Africa. *Emerging Infectious Diseases.* 2006;12(5).

© 2018 Teko et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

The peer review history for this paper can be accessed here:  
<http://www.sdiarticle3.com/review-history/46555>